Massive Bio
Stopped· since Aug 5, 2026
- 52
- days it ran
- 0
- relaunches
Ad copy
Patients with HER2-mutant, treatment-naïve non-squamous NSCLC may qualify for a first-line clinical trial. Identify and refer eligible cases.
🪄Crush AI
Like this ad? Make it yours.
Crush rebuilds this exact creative around your product — your brand, your colors, your offer — in about a minute.
